| Guo, Jun |
| Active, not recruiting | 3 | 390 | RoW | CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus | AnewPharma | Renal Cell Cancer Metastatic | 02/21 | 12/21 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer |
|
|
| Active, not recruiting | 3 | 421 | RoW | Biological : Toripalimab Drug: Axitinib, sunitinib | Shanghai Junshi Bioscience Co., Ltd. | Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | 02/25 | 02/25 | | |
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 364 | RoW | Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Locally Advanced or Metastatic Urothelial Carcinoma | 11/23 | 11/25 | | |
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma |
|
|
| Completed | 3 | 256 | RoW | JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma, Unresectable Melanoma | 07/23 | 11/23 | | |
NCT06738251: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 402 | RoW | SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Urothelial Carcinoma | 07/26 | 09/27 | | |
NCT05647954: A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver |
|
|
| Not yet recruiting | 3 | 350 | RoW | HX008 + TACE, Temozolomide + TACE, Pembrolizumab | Taizhou Hanzhong biomedical co. LTD | Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms | 12/24 | 06/25 | | |
| Recruiting | 3 | 340 | RoW | OH2, Salvage chemotherapy or best supportive care | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 03/25 | 03/26 | | |
NCT05998902: Optimizing Early Nutrition Support in Severe Stroke-2 |
|
|
| Recruiting | 3 | 546 | RoW | Trophic enteral feeding combined with supplemental parenteral nutrition, Full enteral feeding | Wen Jiang-3, Tang-Du Hospital, Xi'an Central Hospital, Xi'an Gaoxin Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.3 Hospital, First People's Hospital of Xianyang, Nanfang Hospital, Southern Medical University, Tongji Hospital, Qilu Hospital of Shandong University, The Second Hospital of Shandong University, PLA 960 Hospital, Daping Hospital, The Third Military Medical University (Army Medical University), The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, First Hospital Affiliated to Zhengzhou University, Gansu Provincial Central Hospital, The First Hospital of Changsha City, Shaanxi Provincial People's Hospital, Yulin No.2 Hospital, Yulin No.1 Hospital, Xijing Hospital | Severe Stroke, Acute Stroke, Dysphagia | 07/26 | 10/26 | | |
NCT05789043: Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma |
|
|
| Recruiting | 3 | 140 | RoW | camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab | Peking University Cancer Hospital & Institute | Acral Melanoma | 08/26 | 02/27 | | |
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma |
|
|
| Recruiting | 3 | 452 | RoW | RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin | RemeGen Co., Ltd. | Urothelial Carcinoma, HER2-expressing | 12/26 | 04/28 | | |
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma |
|
|
| Recruiting | 3 | 165 | RoW | tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin | Shanghai Kechow Pharma, Inc. | Melanoma | 09/27 | 09/27 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Active, not recruiting | 2 | 119 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Melanoma | 08/20 | 11/21 | | |
RC48-C009, NCT03809013: A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 64 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Urothelial Carcinoma | 03/21 | 06/23 | | |
NCT03917069: Nab-PCE vs PC for MM After Failure of Anti-PD-1 |
|
|
| Recruiting | 2 | 145 | RoW | Chemotherapeutic Combinations, chemotherapy | Peking University Cancer Hospital & Institute | Advanced Melanoma | 09/21 | 09/22 | | |
| Not yet recruiting | 2 | 26 | RoW | Lenvatinib, Pembrolizumab, Biological: Pembrolizumab IV infusion Other Names: MK-3475; KEYTRUDA®, Drug: Lenvatinib Oral capsule Other Names: MK-7902; E7080; LENVIMA® | Beijing Cancer Hospital | Mucosal Melanoma, Neoadjuvant Treatment | 12/21 | 12/23 | | |
| Active, not recruiting | 2 | 220 | RoW | humanized anti-PD-1 monoclonal antibody Toripalimab, JS001, TAB001, high-dose recombinant interferon a-2B, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Intron A | Shanghai Junshi Bioscience Co., Ltd. | Mucosal Melanoma | 04/22 | 04/25 | | |
NCT03941795: Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma |
|
|
| Recruiting | 2 | 99 | RoW | JS001(Toripalimab Injection), Axitinib 1 MG [Inlyta], JS001 and Axitinib | Peking University Cancer Hospital & Institute | Advanced Mucosal Melanoma | 06/22 | 12/22 | | |
NCT04200040: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients |
|
|
| Recruiting | 2 | 165 | RoW | OrienX010 injection, Recombinant Human GM-CSF Herpes Simplex Virus Injection, Dacarbazine (DTIC) | OrienGene Biotechnology Ltd. | Melanoma (Skin) | 12/22 | 12/22 | | |
| Completed | 2 | 100 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 02/23 | 02/23 | | |
NCT05274438: Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut |
|
|
| Recruiting | 2 | 37 | RoW | JS001+Imatinib mesylate | Beijing Cancer Hospital | Advanced Melanoma | 03/23 | 04/23 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT05135715: A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) |
|
|
| Recruiting | 2 | 50 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Melanoma, Stage II, HER2-positive, Advanced Melanoma | 12/24 | 12/25 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
NCT06227156: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin Injection, DV,RC48 | RemeGen Co., Ltd. | Castration-resistant Prostate Cancer | 12/25 | 06/26 | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT05051865: To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma |
|
|
| Recruiting | 2 | 60 | RoW | camrelizumab, SHR1210, SHR1020 | Peking University Cancer Hospital & Institute | Melanoma | 08/24 | 08/24 | | |
NCT05263453: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation |
|
|
| Recruiting | 2 | 104 | RoW | HL-085, Vemurafenib | Shanghai Kechow Pharma, Inc. | Melanoma | 09/24 | 12/24 | | |
NCT04462965: Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study |
|
|
| Recruiting | 2 | 294 | RoW | Toripalimab, Temozolomide | Beijing Cancer Hospital | Mucosal Melanoma | 11/24 | 06/25 | | |
SHR-4602-202, NCT06704828: A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 20 | RoW | SHR-4602 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 04/27 | 04/27 | | |
MIZAR-003, NCT06703398: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 98 | RoW | GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin | Shanghai Juncell Therapeutics | Melanoma | 07/26 | 12/26 | | |
NCT05512481: Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab, Apatinib, Temozolomide | Peking University Cancer Hospital & Institute | Melanoma, Acral Melanoma, Temozolomide, Apatinib, Camrelizumab, Neoadjuvant, Pathological Response | 12/24 | 12/25 | | |
NCT06797297: A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy |
|
|
| Not yet recruiting | 2 | 180 | RoW | IBI363, Pembrolizumab | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 03/26 | 06/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 15 | RoW | ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg | Lee's Pharmaceutical Limited | Urothelial Carcinoma | 02/20 | 06/23 | | |
NCT03973151: Study of HL-085 in NRAS Mutant Advanced Melanoma |
|
|
| Completed | 1/2 | 42 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 01/21 | 01/21 | | |
NCT06127238: Study of ST-1898 in Advanced Renal Cell Carcinoma |
|
|
| Recruiting | 1/2 | 90 | RoW | ST-1898 tablets | Beijing Scitech-Mq Pharmaceuticals Limited | Advanced Renal Cell Carcinoma | | | | |
NCT05258266: A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 76 | RoW | ZX-101A | Nanjing Zenshine Pharmaceuticals | Advanced Solid Tumor | 06/23 | 04/24 | | |
NCT06359860: A Study of ST-1898 for Unresectable or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 64 | RoW | ST-1898 tablets | Beijing Scitech-Mq Pharmaceuticals Limited | Unresectable or Metastatic Melanoma | 09/25 | 09/25 | | |
NCT04616443: OH2 Injection in Combination With HX008 for Melanoma. |
|
|
| Recruiting | 1/2 | 60 | RoW | OH2 injection, HX008 injection | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04618393: A Study of EMB-02 in Participants With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 47 | US, RoW | EMB-02 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumors | 07/23 | 03/24 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
NCT06209580: AMT-253 in Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 96 | RoW | AMT-253 for injection | Multitude Therapeutics Inc. | Malignant Melanoma, Advanced Solid Tumors | 04/25 | 12/25 | | |
| Recruiting | 1/2 | 30 | RoW | OH2 injection, Keytruda, pembrolizumab | Binhui Biopharmaceutical Co., Ltd. | Solid Tumor, Melanoma | 03/25 | 12/25 | | |
NCT06727630: A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 40 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Melanoma | 04/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | SHR-A2102, SHR-A2102 ; Adebrelimab injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 07/27 | 07/27 | | |
| Recruiting | 1/2 | 5 | RoW | Ofatumumab, Arzerra | Tang-Du Hospital, Henan Provincial People's Hospital | Neuromyelitis Optica Spectrum Disorder | 06/24 | 12/24 | | |
| Recruiting | 1/2 | 84 | RoW | KD6001, Toripalimab, JS001 | Shanghai Kanda Biotechnology Co., Ltd. | Melanoma | 12/24 | 12/25 | | |
NCT05983237: Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma |
|
|
| Not yet recruiting | 1/2 | 50 | NA | Fluzoparib Camrelizumab Temozolomide | Jun Guo | Melanoma | 12/24 | 12/25 | | |
NCT05794425: Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders |
|
|
| Recruiting | 1/2 | 100 | RoW | Cyclosporine A, Umbilical cord blood & Umbilical cord derived mesenchymal stem cells | Shandong Qilu Stem Cells Engineering Co., Ltd., Shandong Provincial Third Hospital, Dezhou People's Hospital, Children's Hospital Affiliated to Shandong University, The Second Affiliated Hospital of Shandong First Medical University, Tai'an Central Hospital, Linyi People's Hospital, Linyi Central Hospital, Rizhao People's Hospital, Lanling People's Hospital, Shandong Jining No.1 People's Hospital, The affiliated hospital of Jining medical college, Zibo municipal hospital, Binzhou People's Hospital, The Affiliated Hospital of Binzhou Medical College, Shengli Oilfield Central Hospital, Weihai Municipal Hospital, Weihai Central Hospital, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine (TCM), Wuwei People's Hospital, Gansu Wuwei Tumour Hospital, The Second Affiliated Hospital of Harbin Medical University, Yuncheng Institute of Hematology, Kaifeng Central Hospital, Zhengzhou Central Hospital, Air Force Hospital of Western War Zone, The First People' s Hospital of Yunnan Province, Zigong No.1 Peoples Hospital, The First People's Hospital of Jingzhou, Jiangxi Province Children's Hospital, Second Affiliated Hospital of Zhengzhou University, Shandong University of Traditional Chinese Medicine, Yantai Ludong Hospital (Shandong Provincial Hospital Group) | Bone Marrow Failure Disorders | 04/25 | 04/26 | | |
| Recruiting | 1/2 | 20 | RoW | GC101 TIL | Shanghai Juncell Therapeutics | Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy, Adverse Drug Event | 04/25 | 07/25 | | |
Triumph-01, NCT05909436: Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors |
|
|
| Recruiting | 1/2 | 107 | RoW | GLS-012, GLS-010 | Guangzhou Gloria Biosciences Co., Ltd. | Solid Tumor | 12/26 | 12/26 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
TWP-101-11, NCT04871334: Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 1a/1b | 76 | RoW | TWP-101, Sytalizumab Injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Melanoma, Advanced Urothelial Carcinoma | 10/22 | 12/22 | | |
NCT06049030: A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 1a/1b | 190 | NA | HS-10516 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Renal Cell Carcinoma | 09/24 | 09/25 | | |
OrienX010-II-11, NCT04206358: Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma |
|
|
| Recruiting | 1 | 30 | RoW | OrienX010 combination with JS001, Recombinant Human GM-CSF Herpes Simplex Virus Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody Injection | Peking University Cancer Hospital & Institute | Melanoma | 02/21 | 12/23 | | |
| Active, not recruiting | 1 | 33 | RoW | OrienX010 Combination with Toripalimab injection, Recombinant Human GM-CSF Herpes Simplex Virus intratumoral Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody infusion | Peking University Cancer Hospital & Institute | Melanoma | 05/21 | 05/25 | | |
NCT04756934: A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 63 | RoW | HX008, LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Melanoma | 08/21 | 08/22 | | |
NCT03932253: MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) |
|
|
| Suspended | 1 | 79 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Melanoma | 04/23 | 04/24 | | |
NCT04842630: A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 11 | RoW | SHR-1916 | Jiangsu HengRui Medicine Co., Ltd. | Unspecified Adult Solid Tumor, Protocol Specific | 11/22 | 11/22 | | |
NCT04403347: Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention |
|
|
| Recruiting | 1 | 90 | RoW | Innovative Dietary Formulation (Patent ID: CN110250417A), Losartan 50mg per day, Antihypertensive Medication | Chinese Academy of Medical Sciences, Fuwai Hospital, National Natural Science Foundation of China | Hypertension | 01/23 | 09/23 | | |
TQB2618-Ib-01, NCT05451407: Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 50 | RoW | TQB2618 injection, Toripalimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Melanoma | 10/23 | 12/23 | | |
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003 and Triprilimab, HBM4003 | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 11/23 | 11/23 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 07/25 | 12/25 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/25 | 12/25 | | |
NCT06155084: A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients |
|
|
| Recruiting | 1 | 62 | RoW | HP518 - Dose Escalation, Part 1 - Dose Escalation, HP518 -Dose Expansion, Part 2 - Dose Expansion Oral tablet(s) | Hinova Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 09/26 | | |
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | 06/25 | 06/25 | | |
NCT06220838: Study SC-101 in Subjects with Advanced Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | SC-101 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 156 | RoW | JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection | Shanghai Junshi Bioscience Co., Ltd. | Melanoma, Renal Carcinoma, Urothelial Carcinoma | 02/24 | 08/24 | | |
NCT06321250: A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 80 | RoW | JMKX003948 | Jemincare, Zhejiang Hangyu Pharmaceutical Co., Ltd | Renal Cell Carcinoma Metastatic | 05/26 | 04/27 | | |
NCT05387928: A Study of KL340399 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | KL340399 injection | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 05/25 | 05/25 | | |
| Not yet recruiting | 1 | 60 | RoW | AK104+Axitinib, Cadonilimab, AK112+Axitinib, Ivonescimab | Peking University Cancer Hospital & Institute | Melanoma, Mucosal Melanoma, Metastatic Melanoma | 12/25 | 12/27 | | |
NCT05549804: A Study of Intratumoral KL340399 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | KL340399 Intratumoral | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 06/25 | 06/25 | | |
NCT05148325: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 64 | RoW | BAT4706 | Bio-Thera Solutions, Peking University Cancer Hospital & Institute | Advanced Solid Tumor, Melanoma | 12/24 | 12/24 | | |
NCT05773937: A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 12/24 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | 1 | 252 | RoW | SHR-A2102 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Or Metastatic Solid Tumor Malignancies | 08/25 | 08/25 | | |
NCT05766527: A Study of KM602 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 38 | RoW | KM602 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/26 | | |
NCT06054932: Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | LK101 injection | Beijing Likang Life Science and Tech Co., Ltd. | Advanced Solid Tumor | 12/25 | 03/26 | | |
TREAT-OMG, NCT04182984: TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study |
|
|
| Recruiting | N/A | 200 | RoW | Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil), Pyridostigmine Bromide, Prednisone,Azathioprine, Tacrolimus, Mycophenolate Mofetil, | Tang-Du Hospital | Ocular Myasthenia Gravis | 11/24 | 11/24 | | |
NCT04234620: Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . |
|
|
| Not yet recruiting | N/A | 800 | RoW | Toripalimab injection | Shanghai Junshi Bioscience Co., Ltd. | Melanoma, Lung Cance, Breast Cancer | 02/23 | 07/23 | | |
